Safety and Efficacy of Two Dosages of Inhaled TPI ASM8 Compared to Placebo in Mild to Moderate Asthmatic Patients

PHASE2TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

November 30, 2007

Study Completion Date

December 31, 2007

Conditions
Asthma
Interventions
DRUG

TPI ASM8

0.25mg, 0.5mg for 14 days, daily dosage

DRUG

ASM8

inhalation 0.25mg daily for 14 days

Trial Locations (10)

T2N 4N1

Calgary COPD & Asthma Program, Calgary

T6G 2B7

University of Alberta Hospital, Edmonton

V5Z 1M9

Gordon and Leslie Diamond Health Care Centre, Vancouver

V6Z iY6

St-Paul's Hospital, Vancouver

L8N 3 Z5

McMaster University Hospital, Hamilton

L8N 4A6

Firestone Institute for Respiratory Health, Hamilton

K7L: 1O6

Kingston General Hospital, Kingston

H2X 2P4

Institut Thoracique de Montreal, Montreal

H4J 1G5

Hopital Sacre Coeur, Montreal

G1V 4G5

Hopital Laval- Centre de recherche de Cardiologie et Pneumologie, Québec

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Syntara

INDUSTRY